Rheumatoid Arthritis

Stem cells from fat, cord blood and bone marrow are being investigated as possible treatments for Rheumatoid Arthritis. Click on the link provided to find out more about each trial. It remains too early to know which approach will be most suitable. We need evidence collected in clinical trials to determine if a proposed stem cell treatment is both safe and effective.

tagged as Rheumatoid Arthritis

  • Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis Location: China
    Overview: This trial aims to investigate the effect of donated umbilical cord blood stem cells in the treatment of Rheumatoid Arthritis. The trial is being conducted by the 323 Hospital of Chinese People's Liberation Army Xi'an in Shaanxi in conjunction with Alliancells Bioscience Corporation Ltd. The study proposes to recruit 150 patients with confirmed rheumatoid arthritis between July 2012 and December 2013. The participants will receive a single intravenous injection of donated umbilical cord cells. Participants will be assessed for complications and for changes in their immune profile and other activity and pain measures over a six month period.
    Link to Clinical Registry
    Trial Design: Safety and Efficacy Study
    Status: Not yet started
    Stem Cell: Umbilical Cord Stem Cells
  • Long Term Follow-up of Patients with Severe Systemic Sclerosis and Rheumatoid Arthritis who have Undergone Haematopoietic Stem Cell Transplantation Location: Australia
    Overview: This observational study is a retrospective review of patients with severe systemic sclerosis and rheumatoid arthritis that have had a blood stem cell transplantation as a means of immunosuppression to achieve disease remission. The study is being conducted by the Haematology Department of St Vincent's Hospital in Sydney. Patients identified to have had haematopoietic stem cell transplantation in the previous 15 years for systemic sclerosis and rheumatoid arthritis will be invited to participate in this study. The participants will be required to fill out questionnaires documenting and quantifying the progress, current state of their illness and how it impacts their daily life. After reviewing this information, suitable patients will be invited to attend an interview where details of their medical history and prior procedure will be recorded. All this information will be used to record the primary outcome measure i.e. safety and effectiveness of Haematopoietic Stem Cell Transfer (HSCT). The patients will also be required to have a sample of blood drawn for stem cell markers to determine the degree of disease activity. The trial began in August 2008 with a view to recruiting 25 patients is still open and recruiting patients.
    Link to Clinical Registry
    Trial Design: Observational Study
    Status: Open - Recruiting
    Stem Cell: Adult Bone Marrow Stem Cells